Claims

1. A method for treating a patient in need of a drug metabolized primarily by CYP3A, which comprises detecting CYP3A levels in said patient.

2. The method of claim 1, wherein the drug metabolized primarily by CYP3A is nemorubicin.

3. A method for optimizing the therapeutic efficacy of a drug metabolized primarily by CYP3A in a patient in need thereof, which comprises predicting the sensitivity of the patient towards said drug through the detection of CYP3A levels in a biological sample of said patient and selecting a therapeutically effective amount of said drug based on the above CYP3A levels.

4. The method of claim 3, wherein the drug metabolized primarily by CYP3A is nemorubicin.

5. A method for treating a cancer sensitive to a drug metabolized primarily by CYP3A, which comprises:

(a) obtaining a biological sample from a patient suffering from said cancer;

(b) detecting the amount of CYP3A in said sample; and

(c) selecting a therapeutically effective amount of said drug based on the above CYP3A levels.

6. The method of claim 5, wherein the drug metabolized primarily by CYP3A is nemorubicin.

7. A method for predicting patient's sensitivity to a drug, wherein said drug is metabolized by CYP3A, said method comprising determining levels of CYP3A in said patient and wherein the patient's sensitivity to said drug is effected by CYP3A activity.

8. The method of claim 7, wherein the drug metabolized by CYP3A is nemorubicin.

9. A kit for detecting the amount of CYP3A in a biological sample for use in a method for treating a cancer sensitive to a drug metabolized by CYP3A.

10. The kit of claim 9, wherein the drug metabolized by CYP3A is nemorubicin.